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Background: Psychiatric disorders are equally common during pregnancy as among non-pregnant women, and
many of these conditions are treated with psychotropic medicines. Relatively little is known about patterns of use
of many these agents during pregnancy, and specifically of how rates may have shifted during the last decade. We
aimed to quantify the rate of pregnancy related exposures to categories of psychotropic medicines stratified according
to the primary indication for use (antidepressants, antipsychotics, anxiolytics, and psychostimulants), trimester of
pregnancy, trends over time and region, and indication for use.
Methods: We conducted a retrospective cohort study of pregnancies among women in the Truven Health MarketScan
database (source population 70 million Americans), which captures person-specific clinical use and includes detailed
information on filled prescriptions, hospitalizations and outpatient visits for all privately insured employees and their
dependents. We classified psychotropic medicines of interest using ATC level 3 accordingly: antipsychotics (N05A);
anxiolytics (N05B); antidepressants (N06A); psychostimulants, agents used for ADHD and cognitive enhancement
(N06B). We also examined temporal and regional trends in use.
Results: We included 343,299 women who had a live birth between Jan 1, 2006 and Dec 31, 2011, of whom 10.3%
were dispensed one or more psychotropic medicines during pregnancy. This rate varied from 6% to 15% between
states. The rate of use of psychotropic medicines was relatively stable between 2006 and 2011. The most
commonly used psychotropic medicines were selective serotonin reuptake inhibitors (5.1%) and benzodiazepine
or benzodiazepine-like medicines (3.9%). Among psychotropic users, the most commonly associated psychiatric
diagnosis was depression (25.0%), followed by anxiety disorders (24.4%). Approximately 1.6% of women used
more than one category of psychotropic medicine in pregnancy, most commonly an antidepressant and an
anxiolytic medicine (1.2%).
Conclusions: Given this relatively high rate of use, the lack of evidence that the most frequently used medications
improve birth outcomes and the safety concerns associated with both early and late pregnancy use for many
frequently-used medications, there is a need for further study of factors driving psychotropic medication use during
pregnancy.
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In North America, there is evidence that use of psy-
chotropic medicines during pregnancy, especially anti-
depressants, became increasingly prevalent in the early
2000’s [1]. Pregnancy was historically considered protective
against mental health disturbances. More recent commen-
taries highlight pregnancy as a high-risk period [2]. Neither
appears to be the case, with the most reliable estimates
suggesting no significant difference in the rates of the
most commonly diagnosed psychiatric disorders between
pregnant and non-pregnant women of childbearing age,
after adjustment for ethnicity, social class, age, health sta-
tus and stressful life events [3-5]. The principal psychiatric
disorders encountered during pregnancy include major
depressive disorder, anxiety disorders, bipolar affective
disorder, and schizophrenia [6]. These conditions are
often treated with psychotropic medicines, and little is
known about patterns of use of many these agents during
pregnancy, and specifically of how rates may have shifted
during the last decade.
While patterns of use during pregnancy of some cat-
egories of psychotropic medicines, most notably selective
serotonin reuptake inhibitor (SSRI) antidepressants, have
been well studied, estimates of the rate of use vary widely.
For example, studies from the Nordic countries have re-
ported that fewer than 2% of women use antidepressants
during pregnancy [7], whereas one study in a Medicaid
population in Tennessee reported use in 13.4% of all preg-
nancies [1]. Rates of use have also changed considerably
over time [8-10]. This suggests that both temporal and
geographic factors are important in understanding use
of psychotropic medicines during pregnancy. These
differences may reflect a range of factors, including
underlying prevalence, rates of diagnosis and care seeking,
and proportions with drug versus non-drug treatment.
The way that psychotropic medicines are prescribed has
also shifted over time. For example, use of antipsychotics
has increased, and the approved indications for anti-
psychotic drugs have expanded beyond psychotic dis-
orders to include bipolar, major depressive, and anxiety
disorders [11]. Previous research also suggests that the
rate of antipsychotic use during pregnancy has been
increasing [12]. ADHD is increasingly being diagnosed
among adults as well as children [13]. Diagnosis and
treatment of more than one mental health disorder at a
time is not uncommon, and depression and anxiety disor-
ders are often diagnosed as comorbid conditions [14-16].
A common methodological limitation to all studies
examining outcomes of prescription drug use during preg-
nancy is confounding by the underlying indication for the
medicine use and other systematic differences at baseline
affecting both treatment decisions and outcomes. This is
likely to be especially important for women who have
multiple mental health disorders, as their outcomes maybe confounded by their comorbid condition, and they may
be exposed to more than one psychotropic medication.
Thus, examining the use of one category of psychotropic
medicine during pregnancy is unlikely to present a
complete picture of the pharmacologic exposure of the
infant or the mental health of the pregnant woman.
Risks to the infant may also be higher with exposure to
more than one class of psychotropic medicine. Oberlander
et al. found higher risks of congenital heart defects among
infants whose mothers were using both SSRI antidepres-
sants and benzodiazepines during pregnancy [9]. Thus,
understanding the complete picture of exposures to psy-
chotropic medicines during pregnancy is important.
In this study we aim to quantify the rate of pregnancy
related exposures to categories of psychotropic medicines
stratified according to the primary indication for use
(antidepressants, antipsychotics, anxiolytics, and psychos-
timulants), trimester of pregnancy, trends over time and
region, and indication for use. We are especially interested
in the proportion of women using different classes of
drugs who initiate use during pregnancy, versus ongoing
exposures among established users. We also examined the
use of medicines from more than one category during
pregnancy (e.g. an antidepressant and an anxiolytic). De-
fining how commonly psychotropic medicines are used
during pregnancy, which psychotropic medicines are most
often prescribed, what conditions are most commonly
treated with psychotropic medicines, and how psychotropic
conditions are managed during pregnancy will help define
new research priorities in this field.
Methods
We conducted a retrospective cohort study of pregnancies
among women in the Truven Health MarketScan database
(source population 70 million), which captures person-
specific clinical use and includes detailed information on
filled prescriptions, hospitalizations and outpatient visits
for all insured employees and their dependents. These
data come from a selection of large employers, health
plans and government and public organizations (ap-
proximately 100 payers) across multiple states in the
United States. Ethics approval was obtained from the
Behavioral Research Ethics Board at the University of
British Columbia.
Study cohort
We included data from the first pregnancy for each
mother that ended in a live birth in hospital between Jan
1, 2006 and Dec 31, 2011. Our data set includes primipar-
ous and multiparous women, the latter with live births
prior to 2006. Pregnancies were captured in the inpatient
and outpatient data using ICD-9 diagnostic codes indicat-
ing delivery in the maternal hospital record and outpatient
record. To ensure complete capture of prescription drugs
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women who were enrolled continually during preg-
nancy and the three months pre-conception with no
more than a one-month gap in their health insurance
enrollment. As gestational age varied, the total number
of months in which the women needed to be enrolled
in the health insurance plan varied with it.
Definitions of pregnancy periods
Maternal hospital records provided the date of admission
for each in-hospital birth, but not the date of birth. We as-
sumed that the date of admission was equal to the delivery
date. The pregnancy period was built using the algorithm
developed by Li et al., which was shown to correctly
classify medication exposure status in most live born
deliveries with a sensitivity and positive predictive value
of ≥95% and a specificity and negative predictive value
of almost 100% [17]. Using the gestational age (in days)
calculated from the algorithm we estimated a date of
conception by subtracting gestational days from the ad-
mission date. From this estimated conception date, we
built several time periods for analysis of psychotropic drug
exposures: 1) weeks 1 to 13 of gestation (first trimester);
2) Weeks 14 to 26 of gestation (second trimester), 3) week
27 of gestation to delivery (third trimester), 4) 6 months
prior to conception (preconception) and, 5) six months
postpartum (postpartum).
Psychotropic drug use in pregnancy
Outpatient prescription drug claims include prescriptions
dispensed to women at eligible pharmacies either through
a mail-order or card program prescription drug claim,
capturing all prescriptions dispensed that are covered by
her insurance plan. We classified psychotropic medicines
of interest using ATC level 3 accordingly: antipsychotics
(N05A); anxiolytics (N05B); antidepressants (N06A);
psychostimulants, agents used for ADHD and cognitive
enhancement (N06B). Additional file 1 outlines all med-
icines in each category that were dispensed to a woman
in our cohort during pregnancy. We excluded the caf-
feine and caffeine combinations that were included in
N06B. We did not remove medicines that we suspected
were being prescribed for non-psychological indications,
such as the typical antipsychotics that appear to be used
primarily as antiemetics, as these prescriptions still repre-
sent exposures to a psychotropic medicine from one of
the relevant drug classes. We also present frequencies of
women who filled prescriptions from more than 2 cat-
egories of psychotropic medicines during the perinatal
period, and the use of 2 or more different antidepressant
medicines during the perinatal period.
We defined exposure to a psychotropic medicine during
pregnancy and according to trimester if a prescription was
filled on a date within the relevant pregnancy period. Toaccount for the possible overestimation that might result
from including psychotropic medicines filled only once in
the first trimester, we also present conservative numbers
of exposures during pregnancy where we have removed
women who filled only 1 prescription during the first tri-
mester of pregnancy, as these might represent prescrip-
tions filled prior to knowledge of the pregnancy and not
used once the woman became aware she was pregnant.
Patterns of prescription drug exposure
We defined prevalent users of psychotropics during
pregnancy as women for whom the psychotropic was
dispensed in the 6 months prior to pregnancy and then
again in pregnancy. In contrast, incident users were
those with no prescription for the psychotropic in the
6-months before pregnancy. Again we also present
conservative estimates by removing the women who
only filled one prescription for the psychotropic of interest
in the first trimester from both groups. Finally we present
incident use of psychotropic medicines in the postpartum
period, defined as initiation of use during the 180 days
following delivery. These women had no prescription for
the psychotropic agent before or during pregnancy.
Description of associated conditions
Medical conditions associated with use of psychotropics
were identified using the International Classification of
Diseases, Ninth Revision diagnosis codes in the patient’s
hospital and outpatient records between 180 days before
our estimated conception date and delivery. Additional
file 2: Table S1 outlines the diagnostic codes used. The
frequency of these conditions was determined in (1) all
patients exposed to psychotropics agents during pregnancy
(2) patients exposed to each category of psychotropic
medicine (3) according to incident or prevalent use of psy-
chotropic medicines and for the two most commonly used
categories of psychotropic medicines, antidepressants and
anxiolytics and (4) among women who did not fill pre-
scriptions for psychotropic medicines in pregnancy.
Temporal and regional trends in psychotropic medicine
use during pregnancy
We examined the trends in exposure to any psychotropic
medicine during pregnancy and to each category of psycho-
tropic medicines annually from 2007 to 2011 according to
the year of delivery. We examined regional variations
in psychotropic prescribing by examining frequency of
exposure to psychotropic medicines, antidepressants
and anxiolytics by state.
Statistical analyses
All analyses were descriptive of this commercially insured
population. The results are parameters for this particular
population rather than estimates based on a sample and
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analyses were performed using either Stata version 13.0 (Col-
lege Station, TX) or SAS version 9.3 (SAS Institute, Cary, NC).
Results
There were 343,299 live births between Jan 1, 2006 and
Dec 31, 2011 that met our enrollment criteria (not missing
more than one month of enrollment for the 3 months
prior to conception and during the pregnancy). The mean
age of the women at the time of delivery was 30.3 years
with a standard deviation of 5.6 years (median 30 and
interquartile range 27 to 34); 4,895 (1.4%) pregnancies
were multiple gestations, 29,733 (8.7%) were preterm
deliveries. Overall 35,303 women (10.3%) were prescribed
a psychotropic medicine during pregnancy (this number
drops to 6.8% when we remove women who only filled
one prescription during the first trimester of pregnancy).
24,776 (7.2%) women filled a prescription for a psycho-
tropic medicine during the first trimester, 15,883 (4.6%)
during the second trimester and 18,161 (5.3%) during the
third trimester. The most common category of psychotropic
medicine use during pregnancy was antidepressants, with
22,275 (6.5%) women filling an antidepressant during preg-
nancy (conservative estimates are 15,097 (4.4%)), followed
by anxiolytics which were filled by 14,535 (4.2%) of pregnant
women in our cohort (conservatives estimates are 9,235
(2.7%)). Antipsychotics and stimulants were used during
pregnancy by 2,373 (1.1%) and 2,062 (0.6%) respectively
(Table 1). There were 5,423 (1.6%) women using moreTable 1 Summary measures of psychotropic prescription drug




Any psychotropic 33,995 (9.9) 24776 (7.2)
Antidepressant 23,083 (6.7) 17214 (5.0)
SSRI 16524 (4.8) 12881 (3.8)
SNRI 3170 (0.9) 2175 (0.6)
Tricyclic 1222 (0.4) 611 (0.2)
Other 4390 (1.3) 3085 (0.9)
≥ 2 antidepressants 2776 (0.8) 2132 (0.6)
Anxiolytic 12969 (3.8) 7503 (2.2)
Benzo or benzo-like* 12231 (3.5) 6840 (2.0)
Other 950 (0.3) 809 (0.2)
Antipsychotic 1344 (0.4) 1728 (0.5)
Atypical 899 (0.3) 604 (0.2)
Typical 357 (0.1) 1072 (0.3)
Stimulant/ADHD 2798 (0.8) 1982 (0.6)
≥ 2 categories of psychotropic** 5423 (1.6) 3339 (1.0)
Antidepressant + anxiolytic 4195 (1.2) 2293 (0.7)
*Includes benzodiazepines as well as eszopliclone, zolpiedem, and zaleplon.
**defined as prescriptions for ≥ 1 class of psychotropic medicine during pregnancy
used ≥ 1 medicine within the same class (e.g. two antidepressants).than one category of psychotropic medicine during preg-
nancy, and most of these women were using a combin-
ation of antidepressants and anxiolytics (4,068, 1.2%).
Patterns of prescription drug exposure
Rates of use of all psychotropic medicines were higher in
the 6 months preconception than in the first trimester
and decreased further in the second trimester, likely
reflecting women who stopped medicines after becoming
aware of their pregnancy. This pattern was consistent
across all categories of psychotropic medicine except for
typical antipsychotics, which were used considerably more
in the first trimester of pregnancy, likely as an antiemetic.
The most common class of antidepressants dispensed
during pregnancy were SSRIs which were dispensed to
17,410 (5.1%) of women followed by selective norepin-
ephrine reuptake inhibitors (dispensed to 2,382 or 0.8%
of women). Table 2 lists the most common psychotropic
medicines among each category and includes all medicines
that were used by at least 0.1% of the study population.
Among SSRIs the most commonly dispensed medicines
were sertraline, fluoxetine, and escitalopram with 8,432
(2.5%), 3,605 (1.1%), and 3,481 (1.0%) of women filling
a prescription for these medicines during pregnancy
respectively. Nearly all of the anxiolytics prescribed
were benzodiazepines or benzodiazepine-like medicines
(n = 13,486, 3.9%), the latter including zaleplon, zolpidem,
and eszopiclone. The most common benzodiazepine or








with >1 Rx n (%)
15883 (4.6) 18161 (5.3) 35303 (10.3) 23261 (6.8)
12235 (3.6) 11937 (3.5) 22275 (6.5) 15097 (4.4)
9773 (2.9) 9751 (2.8) 17410 (5.1) 12278 (3.6)
973 (0.3) 805 (0.2) 2382 (0.8) 1075 (0.3)
236 (0.07) 209 (0.06) 784 (0.2) 308 (0.1)
1875 (0.6) 1634 (0.5) 4019 (1.2) 1026 (0.3)
889 (0.3) 676 (0.2) 3521 (1.0) 1613 (0.5)
3881 (1.1) 7002 (2.0) 14535 (4.2) 9235 (2.7)
3391 (1.0) 6686 (2.0) 13486 (3.9) 8613 (2.5)
549 (0.2) 377 (0.1) 1375 (0.4) 757 (0.2)
808 (0.2) 503 (0.1) 2373 (1.1) 1015 (0.3)
315 (0.1) 301 (0.1) 742 (0.2) 388 (0.1)
464 (0.1) 160 (0.05) 1573 (0.5) 995 (0.3)
498 (0.1) 325 (0.1) 2062 (0.6) 545 (0.2)
1431 (0.4) 1519 (0.5) 5423 (1.6) 2390 (0.7)
1064 (0.3) 1247 (0.36) 4068 (1.2) 1630 (0.5)
e.g. a benzodiazepine and an antidepressant; does not include women who
Table 2 Most common psychotropic exposures (not exhaustive of all drug exposures—only medicines that were used
by ≥ 0.1% of the study population)




Number who filled more
than 1 Rx during pregnancy
SSRI 17414 (5.1) 13379 (3.9) 11142 (3.3)
Sertraline 8432 (2.5) 6936 (2.0) 5360 (1.6)
Fluoxetine 3605 (1.1) 2694 (0.8) 2300 (0.7)
Escitalopram 3481 (1.0) 2310 (0.7) 1951 (0.6)
Citalopram 2295 (0.7) 2310 (0.7) 1246 (0.4)
Benzodiazepines (and benzo like) 13486 (3.9) 9399 (2.7) 4304 (1.3)
Zolpidem 8239 (2.4) 7238 (2.1) 2676 (0.8)
Alprazolam 2654 (0.8) 1288 (0.4) 893 (0.3)
Diazepam 1884 (0.6) 384 (0.1) 178 (0.05)
Lorazepam 1233 (0.4) 634 (0.2) 302 (0.1)
Other antidepressants 4019 (1.2) 2658 (0.8) 2164 (0.6)
Bupropion 3399 (1.0) 2351 (0.7) 1925 (0.6)
Trazodone 602 (0.2) 270 (0.1) 189 (0.1)
SNRIs 2382 (0.7) 1474 (0.4) 1377 (0.4)
Venlafaxine 1398 (0.4) 936 (0.3) 875 (0.3)
Duloxetine 795 (0.2) 449 (0.1) 416 (0.1)
Desvenlafaxine 210 (0.1) 100 (0.03) 96 (0.03)
Typical antipsychotics 1573 (0.5) 712 (0.2) 274 (0.1)
Prochlorperazine 1527 (0.4) 682 (0.2) 250 (0.1)
Other anxiolytics 1375 (0.4) 820 (0.2) 375 (0.1)
Buspirone 745 (0.2) 520 (0.2) 288 (0.1)
Scopolamine 535 (0.2) 248 (0.1) 56 (0.02)
Amphetamine 1291 (0.4) 657 (0.2) 633 (0.2)
Cyclic antidepressants 784 (0.2) 385 (0.1) 272 (0.1)
Amitriptyline 490 (0.1) 239 (0.1) 162 (0.05)
Nortriptyline 173 (0.1) 75 (0.02) 56 (0.02)
Atypical antipsychotics 742 (0.2) 465 (0.1) 397 (0.1)
Quetiapine 363 (0.1) 228 (0.1) 191 (0.06)
*Removes women who only filled one prescription in the first trimester.
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(n = 1,884, 0.6%) and lorazepam (n = 1,233, 0.4%).
The majority of typical antipsychotic prescriptions
during pregnancy were for prochloperazine (n = 1527,
0.4%), and nearly half of these prescriptions occurred
only during the first trimester. The conservative number
of women exposed, excluding women with a single pre-
scription in the first trimester, drops to 682 (0.2%). If
prochloperazine was primarily being used as an anti-
emetic, women may have filled a single prescription for
short-term relief of first trimester nausea. As we could
not distinguish between this situation and women who
discontinued drug use when they knew they were pregnant,
we retained the same definition of conservative use as with
other medications. Only 17% of women with prescriptionsfor typical antipsychotics during pregnancy refilled their
prescription (n = 274, 0.1%). The most commonly used
atypical antipsychotic was quetiapine, which has been ap-
proved to treat major depressive disorder. However, use of
quetiapine in pregnancy was uncommon (n = 363, 0.1%).
Table 3 shows the mean, median and interquartile
range for the cumulative numbers of days supply during
the pregnancy among the patients dispensed each category
of psychotropic medicine. The median duration of anti-
depressant use during pregnancy was 90 days with a mean
duration of 125.3 days, reflecting exposure for nearly half
the pregnancy. This duration of exposure was similar
among women using SSRIs and slightly shorter among
women using SNRIs (median 60 days, mean 111.1) and
other antidepressants (median 60 days, mean 100.0 days).
Table 3 For psychotropic medicines dispensed during pregnancy, number of days exposure during pregnancy by type
Median 25th percentile 75th percentile Mean ± SD
Any psychotropic 60 30 160 104 ± 118.2
Antidepressant 90 30 210 125.3 ± 103.2
SSRI 90 30 180 118.9 ± 91.4
SNRI 60 30 180 111.1 ± 98.6
Cyclic 30 30 80 69.1 ± 72.5
Other 60 30 150 100.0 ± 90.3
Anxiolytic 30 10 40 43.2 ± 65.6
Benzo or benzo-like 29 10 40 41.8 ± 64.0
Other 30 12 40 46.7 ± 59.7
Antipsychotic 14 7 30 46.4 ± 81.7
Atypical 60 30 150 103.8 ± 102.5
Typical 8 5 15 14.7 ± 24.4
Stimulant/ADHD 49 30 90 79.8 ± 89.9
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posure of 30 days and a mean of 43.2 days. The shortest
duration of exposure was among the typical antipsychotics,
including prochlorperazine (97% of use in this class),
amitriptyline, chlorpromazine, fluphenazine, haloperidol,
loxapine, perphenazine, thioridazine, and trifluoperazine.
Typical antipsychotics were used for a median of 8 days
and a mean of 14.7 days. Stimulants had median exposure
duration of 49 days (mean 79.8).
Table 4 outlines psychotropic medicine use during
pregnancy according to whether the use represents preva-
lent or incident use in pregnancy. Most use of antide-
pressants during pregnancy represents prevalent use
(n = 15,253, 4.4%; Table 4). In contrast, anxiolytics (primar-
ily benzodiazepines and benzodiazepine-like medicines)
were most often initiated during pregnancy (n = 9,215, 2.7%
incident users versus n = 4271, 1.2% prevalent users). Typ-
ical antipsychotics were also used primarily by incident
users in pregnancy (Table 4).Table 4 Prevalent and incident use of psychotropic medicines
N = 343,299 Prevalent use
in pregnancy
Prevalent use in
pregnancy; > 1 Rx*
Antidepressants 15253 (4.4) 11588 (3.4)
SSRI 10998 (3.2) 8300 (2.4)
Anxiolytics 4574 (1.3) 2992 (0.9)
Benzo** 4271 (1.2) 2742 (0.8)
Antipsychotic 559 (0.2) 365 (0.1)
Typical antipsychotic 27 (0.01) 14 (0.00)
Atypical antipsychotic 480 (0.1) 307 (0.09)
ADHD 1741 (0.5) 886 (0.3)
*Removes women who only filled one prescription in the first trimester.
**benzodiazepine or benzodiazepine like product.Description of associated conditions
Table 5 shows the relevant mental health conditions in
patients with and without psychotropic medicine use
during pregnancy. Of the 35,303 psychotropic medicine
users during pregnancy, just under half had a relevant
diagnosis (49.7%) at any time during pregnancy or in the
six months pre-conception. Of these, the most common
diagnoses were depressive disorders (25.0%) and anxiety
disorders (24.4%); 31.5% of antidepressant users had been
diagnosed with anxiety compared to 35.3% diagnosed with
a depressive disorder. Just under half of all users of stimu-
lants had a diagnosis of ADHD (49.6%) and 72.3% of all
stimulant users had a diagnosis of at least one mental
health disorder. Women who were using more than one
psychotropic during pregnancy were most likely to have at
least one relevant psychiatric diagnosis (73.9%). There
were 11,181 women with a diagnosis of depression and
14,102 women with a diagnosis of an anxiety disorder




pregnancy > 1 Rx*
Incident use
postpartum
7,022 (2.1) 5353 (1.6) 15652 (4.6)
6,416 (1.9) 5079 (1.5) 14625 (4.3)
9961 (2.9) 7100 (2.1) 7583 (2.2)
9,215 (2.7) 6657 (1.9) 7319 (2.1)
1814 (0.5) 854 (0.3) 773 (0.2)
1546 (0.5) 698 (0.2) 326 (0.1)
262 (0.1) 158 (0.05) 447 (0.1)
321 (0.1) 135 (0.04) 604 (0.2)
Table 5 Diagnosed maternal conditions in the year prior to or during pregnancy, stratified by exposure to
psychotropic medicines














Bipolar disorder 1637 (4.6) 1225 (5.5) 581 (4.0) 499 (24.2) 98 (4.1) 1747 (0.6) 634 (11.7)
Major depressive disorder 8814 (25.0) 7874 (35.3) 2414 (16.6) 488 (23.7) 218 (9.2) 11861 (3.9) 2036 (37.5)
Anxiety 8611 (24.4) 7006 (31.5) 3188 (21.9) 487 (23.6) 213 (9.0) 14102 (4.6) 2127 (39.2)
Adj/Acute stress‡ 3176 (9.0) 2335 (10.5) 1261 (8.7) 179 (8.7) 211 (8.9) 8041 (2.6) 725 (13.4)
Schizophrenia 48 (0.1) 28 (0.1) 11 (0.1) 35 (1.7) 1 (0.04) 34 (0.01) 22 (0.4)
Personality disorder 143 (0.4) 116 (0.5) 40 (0.3) 27 (1.3) 3 (0.1) 141 (0.05) 38 (0.7)
Sleep disorder 1799 (5.1) 1130 (5.1) 1033 (7.1) 75 (3.6) 34 (1.4) 3255 (1.1) 472 (8.7)
ADHD 1347 (3.8) 546 (2.5) 292 (2.0) 1023 (49.6) 73 (3.1) 1119 (0.4) 469 (8.6)
At least one relevant diagnosis 17561 (49.7) 13655 (61.3) 5786 (39.8) 1490 (72.3) 1086 (45.8) 25707 (8.3) 4007 (73.9)
‡A diagnosis of adjustment reaction and/or acute stress.
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these diagnoses, respectively. Of the 11,217 women diag-
nosed with acute stress or adjustment disorder, 3176
(28%) were prescribed a psychotropic drug, most often an
antidepressant.
Table 6 shows diagnoses for mental health disorders
according to prevalent and incident use of psychotropic
medicines, antidepressants and anxiolytics (as well as
conservative prevalent and incident use). The rate of users
with a relevant diagnosis is nearly double for prevalent
users of psychotropic medicines compared with incident
users (63.1% versus 31.1% respectively).
Temporal and regional trends
Figure 1 shows psychotropic medicine use during preg-
nancy across each year of study. The figure indicates
remarkable consistency in exposure to psychotropic
medicines during the study period. There was a slight
decrease in antidepressant use between 2010 and 2011
from 6.7% to 6.4%, and the use of stimulants increased
from 0.4% in 2007 to 0.9% in 2011. Figure 2 shows the
rate of psychotropic exposure during pregnancy by
state. Significant regional differences are observed with
the lowest rates of psychotropic use being observed in
New York (6.44%) and California (6.99%) and the highest
rates of use in Idaho (15.41%), Louisiana (14.94%), Utah
(14.80%), West Virginia (14.44%), and South Carolina
(14.17%). A number of the Southern states had higher
than average rates, with Alabama, Arkansas, Kentucky,
Louisiana, North and South Carolina, Indiana, Tennessee
and West Virginia all having rates above 12%.
Discussion
In this analysis of nearly 350,000 pregnancies among
women with private health insurance from across the
United States, we found that at least one psychotropic
medicine was dispensed to 1 in 10 pregnant womenduring pregnancy. The most commonly used medicines
during pregnancy were antidepressants (selective serotonin
reuptake inhibitors specifically) and anxiolytics (benzodi-
azepine and benzodiazepine-like medicines). We also report
that 1.6% of women were using two or more different cat-
egories of psychotropic medicines during pregnancy, most
often an antidepressant and an anxiolytic. The median
duration of exposure was 60 days, ranging from 29 to
90 days for all categories of medications except for typical
antipsychotics, which are often used as antiemetics. Rela-
tively few women received atypical antipsychotics (1.1%)
or stimulants or other drugs for ADHD (0.6%). We found
very little variation in the rate of exposure over the study
period, with approximately 10% of pregnant women using
a psychotropic medicine during pregnancy in each year
between 2007 and 2011.
The most common psychiatric diagnoses in this cohort
in the period from six months pre-pregnancy to the end
of pregnancy was anxiety (n = 22,713) followed by depres-
sion (n = 20,675), with 37.9% and 42.6% of those with each
diagnosis, respectively, receiving psychotropic medications
in pregnancy. The latter is similar to the 40.3% rate of
antidepressant use among women with a relevant diagno-
sis in a national US study of over one million pregnant
low-income women covered by Medicaid from 2000 to
2007 [18]. Among women taking antidepressants, anxiety
diagnoses (31.5%) were nearly as prevalent as depression
diagnoses (35.3%), and there were twice as many antide-
pressants users with an anxiety diagnosis than anxiolytic
users with an anxiety diagnosis (7,006 compared with
3,176).
What do these findings mean for maternal and infant
health and well-being? While the evidence in this area is
complex and often contradictory, and a full evidence
review is beyond the scope of this article, a few areas of
concern merit discussion in order to provide necessary
context for our results. Pregnant women with depression









Psychotropic users N = 20481 N = 15689 N = 14822 N = 10798
Bipolar disorder 1294 (6.3) 1105 (7.0) 342 (2.3) 278 (2.6)
MDD 6724 (32.8) 5680 (36.2) 2084 (14.1) 1730 (16.0)
Anxiety 6450 (31.5) 5266 (33.6) 2153 (14.5) 1651 (15.3)
Sleep disorder 1360 (6.6) 1076 (6.9) 439 (3.0) 319 (3.0)
ADHD 1208 (5.9) 877 (5.6) 139 (1.0) 86 (0.8)
Adj/acute‡ 2098 (10.2) 1652 (10.5) 1078 (7.3) 800 (7.4)
Any relevant diagnosis 12921 (63.1) 10400 (66.3) 4640 (31.3) 3567 (33.0)
Antidepressant users N = 15253 N = 11588 N = 7022 N = 5353
Bipolar disorder 895 (5.9) 721 (6.2) 329 (4.7) 250 (4.7)
MDD 5858 (38.4) 4789 (41.3) 2010 (28.6) 1629 (30.4)
Anxiety 5176 (33.9) 4118 (35.5) 1822 (26.0) 1372 (25.6)
Sleep disorder 844 (5.5) 637 (5.5) 286 (4.1) 210 (3.9)
ADHD 402 (2.6) 315 (2.7) 144 (2.1) 104 (1.9)
Adj/acute‡ 1623 (10.6) 1241 (10.7) 712 (10.1) 532 (9.9)
Any relevant diagnosis 9967 (65.3) 7896 (68.1) 3688 (52.5) 2821 (52.7)
Anxiolytic users N = 4574 N = 2993 N = 9961 N = 7099
Bipolar disorder 325 (7.1) 240 (8.0) 255 (2.6) 181 (2.6)
MDD 1181 (25.8) 826 (27.6) 1227 (12.3) 886 (12.5)
Anxiety 1609 (35.2) 1075 (35.9) 1571 (15.8) 1016 (14.3)
Sleep disorder 596 (13.0) 407 (13.6) 437 (4.4) 294 (4.1)
ADHD 166 (3.6) 119 (4.0) 126 (1.3) 102 (1.4)
Adj/acute‡ 506 (11.1) 332 (11.1) 755 (7.6) 524 (7.4)
Any relevant diagnosis 2753 (60.2) 1858 (62.1) 3033 (30.5) 2080 (29.3)
*Removes women who filled 1 prescription in the first trimester.
‡A diagnosis of adjustment reaction and/or acute stress.
Figure 1 Psychotropic medicine use during pregnancy by year.
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Figure 2 Psychotropic medicine use during pregnancy by state.
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without a psychiatric diagnosis, and this is often used as
a rationale to support drug treatment in pregnancy [19].
However, the evidence on depression and pregnancy
outcomes has been criticized for inadequately addressing
confounding [20], including socio-economic factors
[19,21], psychiatric diagnoses [22] and pregnancy com-
plications [23,24], and it is often unclear whether
depression and anxiety diagnoses precede or follow
pregnancy complications [25]. More importantly, to
date there is no evidence that antidepressants for
depression or anxiolytics for anxiety mitigate poorer
health outcomes among women with depression or
anxiety-related diagnoses [26-28]. The medicines used
to treat these mood disorders have been associated
with poorer birth outcomes [29,30]. Selective serotonin
use in pregnancy has been associated with a number of
adverse health outcomes, including a higher rate of
miscarriage [31], pre-term birth [32], congenital heart
malformations with first trimester exposure [33], and
persistent pulmonary hypertension of the newborn
[34]. The extent to which poorer health outcomes with
antidepressant exposure are a result of unmeasured
confounding by the underlying maternal depression or
anxiety remains an open question [9]. There is less incon-
sistency with respect to postnatal adaptation syndrome, a
syndrome that generally presents as a transient combin-
ation of respiratory distress, jitteriness, abnormal tone,
tremors, restlessness, convulsions, jaundice, rigidity, and
hypoglycaemia [35-38], and occurs in approximately 1/3rd
of newborns exposed to SSRIs in utero [39]. The evidence
on safety of use of atypical antipsychotics is sparse but
tends to suggest an increased risk of NICU admission
among exposed infants; however, the population ofantipsychotic users tends to have much higher rates of
many adverse conditions, which likely confounds this
association [40,41]. There is some evidence from case–
control studies of an increased risk of cleft palate with
benzodiazepine use in the first trimester [42], and a
neonatal withdrawal syndrome following third trimester
use [42,43]. A research study from Taiwan has suggested
that zolpidem, the most frequently used anxiolytic in
our cohort, is associated with poorer infant outcomes;
however, unmeasured confounding is again a very real
problem in this literature [44].
Our results were not consistent with earlier studies
reporting a trend of increased use of psychotropic medi-
cines during pregnancy. Cooper et al. examined a publicly
insured American Medicaid population in Tennessee and
reported that antidepressant use more than doubled be-
tween 1999 and 2003 from 5% to 13% [1]. A more recent
national study of women covered by Medicaid from 2000
to 2007 found that 8.1% were dispensed antidepressants in
pregnancy [18]. They also found that antidepressant use
declined following an FDA warning in 2003 on increased
risk for suicidality in children and adolescents [18]. Al-
though largely irrelevant to use in pregnancy, this may
have led to greater overall caution. The higher rate
reported (8.1% versus our rate of 6.7%) may reflect greater
exposure among women of lower socio-economic status;
however, there is only one year of overlap in the two ana-
lyses, and although we found no difference in exposure
rate from 2007 to 2011, an earlier shift in rate of drug use
may have occurred. Our results regarding higher rates of
use of psychotropic medicines in Southern states is con-
sistent with regional variation in depression diagnoses
among adults reported in US epidemiological surveys
[45]. Our study also indicates higher than average rates in
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differs from disease surveillance surveys but should be
interpreted with caution, as we have some small num-
bers in some of these states (e.g. Idaho n = 785; Kansas
n = 2,833)
We found little use of atypical antipsychotics (0.2%).
Other research has reported an increasing trend in off-
label use of antipsychotics in the general US population,
including, for example, prescribing of quetiapine for
insomnia [11]. While we reported a high rate of use of
typical antipsychotics in the first trimester, given the
median prescription length (8 days) and frequent incident
use in the first trimester, we expect that this represents
use as antiemetics. Prochlorperazine, the most commonly
prescribed typical antipsychotic in our cohort, is indicated
in the U.S. for severe nausea and vomiting. However, the
drug’s label warns against use in pregnancy, “except in
cases of severe nausea and vomiting that are so serious
and intractable that, in the judgment of the physician,
drug intervention is required and potential benefits out-
weigh possible hazards” [46].
Our study is subject to some limitations. Our data are
drawn from a large private insurance claims database
that includes women from across the United States (44
states are represented). However, a large proportion of
births in the US occur to women who are covered by
Medicaid [47], and it is unclear whether our findings
generalize to these women. The same applies to our
state-specific prescribing patterns, which only reflect
prescribing patterns of this commercially insured popu-
lation. However, the general regional trends we present
are consistent with previous studies of prescription drug
use during pregnancy [1,48]. We were also unable to
identify pregnancies that ended in spontaneous abortions,
or therapeutic abortions, a population which may have
higher exposure to psychotropic medicines [31]. Any bias
created through these omissions is likely to be in the dir-
ection of underestimating exposure.
Our measure of exposure is based on pharmacy dis-
pensing of medication, and does not directly measure
medication use by the pregnant women. To account
for this limitation, we provide conservative estimates that
remove women who filled only one prescription in the
first trimester, as these women seem most likely to
have filled prescriptions that might not have been used.
Finally, we had to impute last menstrual period based on
claims for labor and delivery, which provide information
on preterm birth. Although this approach has been shown
to be valid [17], some degree of misclassification is likely.
We are also limited in our ability to detect diagnosed
mental health conditions. While ICD-9 codes are helpful
in identifying conditions, they do not reflect a gold-
standard diagnosis and a preferable measure would be a
diagnostic interview undertaken by a trained health careprovider. We also report that only half of our psychotropic
medicine users had a relevant mental health diagnosis.
While this may reflect some missing diagnostic informa-
tion due to one-month lapses in coverage, it is also con-
sistent with results from the US National Ambulatory
Medical care surveys indicating the lack of psychiatric
diagnosis noted at two-thirds of primary care consulta-
tions at which an antidepressant was prescribed [49].
The fact that many of these medicines are commonly
prescribed for other indications may also be a relevant
factor, as our rates of diagnoses were higher among
women using categories of medicines with less off-label
use (e.g. stimulants to treat ADHD).
Conclusions
In summary, approximately 10% of privately-insured
women in the United States are dispensed one or more
psychotropic medicine during pregnancy, with important
regional variation, around 6% to 15%. The most commonly
used psychotropic medicines are selective serotonin re-
uptake inhibitors and benzodiazepine or benzodiazepine-
like medicines. The most commonly associated psychiatric
diagnosis was depression, followed by anxiety disorders,
which were mainly treated with antidepressants. Approxi-
mately 1.2% of women use both an antidepressant and an
anxiolytic medicine during their pregnancy. Given these
relatively high rates of use, the lack of evidence that the
most frequently used medications improve birth outcomes,
and the safety concerns raised both by early and late preg-
nancy use for many frequently-used medications, there is
a need for further study of factors driving use of these
medicines during pregnancy. For depression and anxiety
disorders, alternative treatment options are available. One
question raised by these findings is the extent to which
pregnant women, and women of reproductive age who
may be planning pregnancy, have equivalent access to
non-drug as to drug options for common mental health
concerns.
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